Oral ibandronate provides significant antifracture efficacy in women with low bone mass

被引:0
|
作者
Miller, PD
Lorenc, R
Harris, ST
Stakkestad, JA
Gilbride, J
Schimmer, RC
机构
[1] CCBR, Lakewood, CO USA
[2] Childrens Mem Hlth Inst, Osteoporot Ctr, Warsaw, Poland
[3] Univ Calif San Francisco, Osteoporosis Ctr, San Francisco, CA 94143 USA
[4] CECOR AS, Haugesund, Norway
[5] F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:S108 / S109
页数:2
相关论文
共 50 条
  • [1] Significant antifracture efficacy of oral ibandronate in women with low bone mass
    Lorenc, R
    Felsenberg, D
    Stakkestad, JA
    Gibride, J
    Schimmer, RC
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 452 - 452
  • [2] Significant antifracture benefit with ibandronate in postmenopausal women with high baseline bone turnover
    Epstein, S
    Rosen, CJ
    Mahoney, P
    Schimmer, RC
    Chesnut, CH
    [J]. OSTEOPOROSIS INTERNATIONAL, 2003, 14 : S72 - S72
  • [3] Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE
    Chesnut, CH
    Ettinger, MP
    Miller, PD
    Baylink, DJ
    Emkey, R
    Harris, ST
    Wasnich, RD
    Watts, NB
    Schimmer, RC
    Recker, RR
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (03) : 391 - 401
  • [4] Efficacy and Safety of Monthly Oral Ibandronate in Postmenopausal Women with Low Bone Density.
    Bolognese, M. A.
    McClung, M. R.
    Sedarati, F.
    Recker, R. R.
    Miller, P. D.
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2008, 23 : S339 - S339
  • [5] Ibandronate-induced reduction of bone turnover marker predicts antifracture efficacy
    Miller, P. D.
    Blackburn, R.
    Grant, R.
    Recker, R. R.
    [J]. CALCIFIED TISSUE INTERNATIONAL, 2007, 80 : S46 - S46
  • [6] Oral ibandronate produces significant antifracture efficacy when given intermittently with a between-dose interval of >2 months
    Felsenberg, D
    Halse, J
    Skag, A
    Gilbride, J
    Schimmer, RC
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 97 - 97
  • [7] Bone remodelling and antifracture efficacy of oral bisphosphonate therapy
    Papapoulos, Socrates E.
    [J]. BONE, 2007, 41 (05) : S32 - S32
  • [8] Increases in Hip and Spine Bone Mineral Density are Predictive for Vertebral Antifracture Efficacy with Ibandronate
    Paul D. Miller
    Pierre D. Delmas
    Hermann Huss
    Katie M. Patel
    Ralph C. Schimmer
    Silvano Adami
    Robert R. Recker
    [J]. Calcified Tissue International, 2010, 87 : 305 - 313
  • [9] Relative change in bone mineral density is a valid surrogate for antifracture efficacy with ibandronate.
    Epstein, S
    Huss, H
    Wilson, KM
    Schimmer, RC
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 : S447 - S447
  • [10] Increases in Hip and Spine Bone Mineral Density are Predictive for Vertebral Antifracture Efficacy with Ibandronate
    Miller, Paul D.
    Delmas, Pierre D.
    Huss, Hermann
    Patel, Katie M.
    Schimmer, Ralph C.
    Adami, Silvano
    Recker, Robert R.
    [J]. CALCIFIED TISSUE INTERNATIONAL, 2010, 87 (04) : 305 - 313